Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

The tripartite toxin produced by Bacillus anthracis is the key determinant in the etiology of anthrax. We have engineered a panel of toxin-neutralizing antibodies, including single-chain variable fragments (scFvs) and scFvs fused to a human constant κ domain (scAbs), that bind to the protective antigen subunit of the toxin with equilibrium dissociation constants (Kd) between 63 nM and 0.25 nM. The entire antibody panel showed high serum, thermal, and denaturant stability. In vitro, post-challenge protection of macrophages from the action of the holotoxin correlated with the Kd of the scFv variants. Strong correlations among antibody construct affinity, serum half-life, and protection were also observed in a rat model of toxin challenge. High-affinity toxin-neutralizing antibodies may be of therapeutic value for alleviating the symptoms of anthrax toxin in infected individuals and for medium-term prophylaxis to infection.

[1]  B. Kroesen,et al.  Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas , 1998, International journal of cancer.

[2]  I. Pastan,et al.  Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3 (*) , 1995, The Journal of Biological Chemistry.

[3]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  G. Georgiou,et al.  In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site. , 1999, Protein engineering.

[5]  A. Plückthun,et al.  Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. , 1997, Journal of immunological methods.

[6]  R. Collier,et al.  Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells , 1991, Infection and immunity.

[7]  H. Khanna,et al.  A Dominant Negative Mutant of Bacillus anthracisProtective Antigen Inhibits Anthrax Toxin Action in Vivo * , 2001, The Journal of Biological Chemistry.

[8]  P. Plateau,et al.  Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. , 1995, Analytical biochemistry.

[9]  P. Turnbull,et al.  Anthrax vaccines: past, present and future. , 1991, Vaccine.

[10]  M. Keller,et al.  Passive immunity in prevention and treatment of infectious diseases. , 2000, Clinical microbiology reviews.

[11]  B. Sellman,et al.  Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax , 2001, Science.

[12]  A. Plückthun,et al.  Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides* , 2001, The Journal of Biological Chemistry.

[13]  Thomas E. Creighton,et al.  Protein structure : a practical approach , 1997 .

[14]  S. Welkos,et al.  The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. , 2001, Microbiology.

[15]  George M. Whitesides,et al.  Designing a polyvalent inhibitor of anthrax toxin , 2001, Nature Biotechnology.

[16]  Pace Cn,et al.  Measuring and increasing protein stability , 1990 .

[17]  J. Ezzell,et al.  Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin , 1984, Infection and immunity.

[18]  M. McPherson,et al.  PCR 2 : a practical approach , 2016 .

[19]  B. Ivins,et al.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs , 1997, Infection and immunity.

[20]  R. Bhatnagar,et al.  Anthrax Toxin , 2001, Critical reviews in microbiology.

[21]  A. Casadevall.  Antibodies for defense against biological attack , 2002, Nature Biotechnology.

[22]  C. P. Quinn,et al.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. , 2001, Emerging infectious diseases.

[23]  R. Brookmeyer,et al.  The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. , 2001, Biostatistics.

[24]  S. Yadav,et al.  MEASURING THE CONFORMATIONAL STABILITY OF PROTEINS , 1992 .

[25]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[26]  W J Harris,et al.  Escherichia coli skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments. , 1999, Protein expression and purification.

[27]  M. Hugh-jones,et al.  The Sverdlovsk anthrax outbreak of 1979. , 1994, Science.

[28]  S. Leppla,et al.  Internalization of a Bacillus anthracis Protective Antigen-c-Myc Fusion Protein Mediated by Cell Surface Anti-c-Myc Antibodies , 1998, Molecular medicine.

[29]  B. Ivins,et al.  In vitro correlate of immunity in a rabbit model of inhalational anthrax. , 2001, Vaccine.

[30]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[31]  S. Reuveny,et al.  Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine , 2001, Infection and Immunity.

[32]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[33]  B. Ivins,et al.  Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin , 1989, Applied and environmental microbiology.

[34]  C. Pace.  Measuring and increasing protein stability. , 1990, Trends in biotechnology.

[35]  A. Hayhurst,et al.  Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain. , 2000, Protein expression and purification.

[36]  S. Reuveny,et al.  Efficiency of Protection of Guinea Pigs against Infection with Bacillus anthracis Spores by Passive Immunization , 2002, Infection and Immunity.

[37]  R Lamb,et al.  Anthrax. , 1973, Red Book (2018).

[38]  J. M. Novak,et al.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. , 1996, Microbiology.

[39]  A. Plückthun,et al.  Tailoring in vitro evolution for protein affinity or stability. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Stemmer.  Rapid evolution of a protein in vitro by DNA shuffling , 1994, Nature.

[41]  L. Nieba,et al.  Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. , 1997, Protein engineering.

[42]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[43]  Aponte Deborah A. Adams Gerald Jones Willie J. Anderson D Connor,et al.  Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. , 2001, MMWR. Morbidity and mortality weekly report.

[44]  John A. Young,et al.  Identification of the cellular receptor for anthrax toxin , 2001, Nature.

[45]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Leppla,et al.  Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin , 1988, Infection and immunity.

[47]  T. Honda.  [Bacterial protein toxins]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.